中国神经再生研究(英文版) ›› 2018, Vol. 13 ›› Issue (3): 402-405.doi: 10.4103/1673-5374.228713

• 综述:神经损伤修复保护与再生 • 上一篇    下一篇

通过松弛素肽激素的神经保护作用 - 对当前研究状况的综述

  

  • 收稿日期:2018-02-03 出版日期:2018-03-15 发布日期:2018-03-15

The relaxin peptide family – potential future hope for neuroprotective therapy? A short review

Marius Nistor1, Martin Schmidt3, René Schiffner1, 2   

  1. 1 Department of Neurology, Jena University Hospital, Friedrich Schiller University, Jena, Germany
    2 Orthopaedic Department, Jena University Hospital, Friedrich Schiller University, Jena, Germany
    3 Institute for Biochemistry II, Jena University Hospital, Friedrich Schiller University, Jena, Germany
  • Received:2018-02-03 Online:2018-03-15 Published:2018-03-15
  • Contact: Marius Nistor,marius.nistor@med.uni-jena.de.

摘要:

orcid:0000-0003-4733-8503(Marius Nistor)

Abstract:

 Since its discovery in the 1920’s the relaxin peptide hormone family has not only grown in number to now seven members (relaxin-1, relaxin-2, relaxin-3, insulin-like peptide (INSL) 3, INSL4, INSL5 and INSL6), but ever more effects, suchs as vasodilatory, angiogenic, anti-apoptopic, anti-fibriotic and anti-inflammatory, have been linked to them. While relaxin-2 has mainly been investigated in the context of cardiac protection, most comprehensively in the RELAX-AHF and RELAX AHF2 studies, a small number of studies have furthermore assessed the potential neuroprotective effects of especially relaxin-2 and other members of the relaxin family. In this short review we summarise and discuss recent efforts to utilize relaxin hormones for neuroprotection and point out potential future fields of research and translational applications. While many questions still need to be answered, the promising results of the available studies definitely warrant future well-designed studies on neuroprotection by relaxin peptides.

Key words: relaxin, relaxin-2, neuroprotection, stroke, hemorrhagic shock, cerebral